Effectiveness and safety evaluation in the dyslipidemia treatment with statins

Effectiveness and safety evaluation in the dyslipidemia treatment with statins

<p>Statins are used to reduce morbidity and mortality in patients with a high risk of cardiovascular disease. However, the use of statins does not ensure effectiveness and pharmacotherapeutic safety. In this context, the present study aimed to evaluate the effectiveness and safety of the thera...

Full description

Bibliographic Details
Main Authors:	André Santos Silva, Túlio Ricardo Couto de Lima Souza, Allan Alves Freitas, Luciane Soares Lima, Almir Gonçalves WAnderley
Format:	Article
Language:	English
Published:	São Paulo State University (UNESP) 2016-07-01
Series:	Revista de Ciências Farmacêuticas Básica e Aplicada
Online Access:	http://seer.fcfar.unesp.br/rcfba/index.php/rcfba/article/view/343

Similar Items

The role of dyslipidemia and statins in venous thromboembolism
by: Rosendaal Frits R, et al.
Published: (2001-07-01)

New Drugs for Treating Dyslipidemia: Beyond Statins
by: Chang Ho Ahn, et al.
Published: (2015-04-01)

Comparação entre o tratamento farmacológico aplicado em crianças de zero a cinco anos atendidas em uma unidade de emergência e as diretrizes do III Consenso Brasileiro no Manejo da Asma Comparison between the drug treatment used in children up to five years of age treated in an emergency room and the guidelines established in the III Brazilian Consensus on Asthma Management
by: Ana Paula Ochoa Santos, et al.
Published: (2007-02-01)

The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis
by: Wenjing Zhou, et al.
Published: (2024-02-01)

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
by: Azar ST, et al.
Published: (2014-05-01)

Does Adjuvant Treatment With Ginkgo Biloba to Statins Have Additional Benefits in Patients With Dyslipidemia?
by: Yu Fan, et al.
Published: (2018-06-01)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
by: Jeongmin Lee, et al.
Published: (2023-11-01)

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
by: Keunhyeong Bak, et al.
Published: (2023-08-01)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
by: Peter Alagona Jr
Published: (2010-05-01)

Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus
by: Sung Hye Kong, et al.
Published: (2017-01-01)

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
by: Benes LB, et al.
Published: (2016-12-01)

The use of statin drugs in patients with chronic kidney disease, combined with dyslipidemia
by: D.D. Ivanov, et al.
Published: (2015-04-01)

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS)
by: Margus Viigimaa, et al.
Published: (2014-01-01)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
by: Lei Zhang, et al.
Published: (2019-06-01)

Safety of statins
by: Debasish Maji, et al.
Published: (2013-01-01)

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL[S]
by: M. John Chapman, et al.
Published: (2020-06-01)

An effect of statin on serum uric acid in patients with dyslipidemia at a tertiary care hospital
by: Anjan Palikhey, et al.
Published: (2023-12-01)

SCREENING FOR DYSLIPIDEMIA AND EXPEDIENCE OF STATIN THERAPY FOR THE CITIZENS OF TRANSCARPATHIA VALLEY REGIONS WITH OVERWEIGHT AND OBESITY
by: A. V. Kedyk, et al.
Published: (2017-07-01)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
by: Elisavet Moutzouri, et al.
Published: (2010-06-01)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
by: Fisman Enrique Z, et al.
Published: (2006-09-01)

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
by: Vasilios Gabriel Athyros, MD, et al.
Published: (2016-09-01)

The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment
by: Adel El Etriby, et al.
Published: (2013-09-01)

Local application of statins in the treatment of experimental periodontal disease in rats
by: Bianca Fernanda Espósito SANTOS, et al.

Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer
by: Kyu-Tae Han, et al.
Published: (2021-05-01)

Persistent dyslipidemia in statin-treated patients: The focus on comprehensive lipid management survey in Swiss patients
by: L Hess, et al.
Published: (2011-05-01)

Cost-effectiveness analysis of statin monotherapy regimen in outpatient management of dyslipidemia in patients with diabetes mellitus
by: Khemachitra Saneewong Na Ayuttaya, et al.
Published: (2014-12-01)

The comparative characteristic of influence separate statin on rheological properties erythrocyre at sick of the arterial hypertension with dyslipidemia
by: I N Medvedev, et al.
Published: (2011-03-01)

Efficacy and safety of rosuvastatin in the management of dyslipidemia
by: Paolo Rubba, et al.
Published: (2009-04-01)

Dyslipidemia in racially admixtured children with cystic fibrosis
by: Cresio Alves, et al.
Published: (2012-01-01)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
by: Alwhaibi M, et al.
Published: (2019-12-01)

The safety of statins in clinical practice.
by: Armitage, J
Published: (2007)

Misrepresentation of statin safety evidence.
by: Armitage, J, et al.
Published: (2014)

STATIN SAFETY REVISITED DATA
by: O. M. Drapkina
Published: (2015-09-01)

STATIN SAFETY REVISITED DATA
by: O. M. Drapkina
Published: (2015-09-01)

Statin safety: myths and reality
by: Zh. D. Kobalava, et al.
Published: (2007-04-01)

Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.
by: Saud N Al Sifri, et al.
Published: (2014-01-01)

STATINES IN PREVENTION AND TREATMENT OF ATHEROSCLEROSIS CONNECTED DISEASES: EFFICIENCY AND SAFETY
by: Y. A. Karpov
Published: (2015-12-01)

STATINES IN PREVENTION AND TREATMENT OF ATHEROSCLEROSIS CONNECTED DISEASES: EFFICIENCY AND SAFETY
by: Y. A. Karpov
Published: (2015-12-01)

Advances in Treatment of Dyslipidemia
by: Jill Dybiec, et al.
Published: (2023-08-01)

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia
by: Alexina Orsoni, et al.
Published: (2016-11-01)